Literature DB >> 24268585

Factors associated with pneumonia in post-cardiac arrest patients receiving therapeutic hypothermia.

Jae-Hyug Woo1, Yong Su Lim2, Hyuk Jun Yang1, Won Bin Park1, Jin Seong Cho1, Jin Joo Kim1, Sung Youl Hyun1, Gun Lee1.   

Abstract

AIM: The aim of this study is to investigate risk factors associated with the development of pneumonia during the first 7 days of admission in survivors of cardiac arrest receiving therapeutic hypothermia.
METHODS: A total of 123 patients receiving therapeutic hypothermia after out-of-hospital cardiac arrest between January 2008 and December 2010 were enrolled. Study populations were categorized as "pneumonia present" [P (+)] and "pneumonia absent" [P (-)] contingent upon the development of pneumonia during the first 7 days of admission. Risk factors and outcomes related to development of pneumonia were determined.
RESULTS: Fifty-nine patients (48.0 %) developed pneumonia, and P (+) patients had lower Acute Physiology and Chronic Health Evaluation II score (22 vs 26); longer durations of central venous catheter (8.9 vs 5.1 days), nasogastric tube (11.1 vs 3.8 days), mechanical ventilation (MV) (9.3 vs 3.7 days), and intensive care unit stay (10.0 vs 5.0 days); and higher rates of nasogastric feeding (66.1% vs 35.9 %), tracheostomy (52.5% vs 17.2 %), and postanoxic seizure (62.7% vs 39.1 %). In multivariate analyses, the occurrence of postanoxic seizure (odds ratio, 2.75; 95% confidence interval, 1.06-7.14; P = .04) and the length of MV (odds ratio, 1.33; 95% confidence interval, 1.15-1.52; P < .001) were independently associated with the development of pneumonia. The development of pneumonia had no significant association with survival (log-rank test, P = .15).
CONCLUSION: Postanoxic seizure and prolonged duration of MV are independently associated with development of pneumonia. It may be helpful that we give more attention to the development of pneumonia in patients with postanoxic seizure and provide prompt diagnosis and treatment of postanoxic seizure.
© 2013.

Entities:  

Mesh:

Year:  2013        PMID: 24268585     DOI: 10.1016/j.ajem.2013.10.035

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  6 in total

1.  The Relationship Between the Decreased Rate of Initial Blood Glucose and Neurologic Outcomes in Survivors of Out-of-Hospital Cardiac Arrest Receiving Therapeutic Hypothermia.

Authors:  Jae-Hyug Woo; Yong Su Lim; Hyuk Jun Yang; Sung Youl Hyun; Jin Seong Cho; Jin Joo Kim; Gun Lee
Journal:  Neurocrit Care       Date:  2017-06       Impact factor: 3.210

2.  Association of multiple rib fractures with the frequency of pneumonia in the post-resuscitation period.

Authors:  Yasuyuki Kawai; Keisuke Takano; Keita Miyazaki; Koji Yamamoto; Yusuke Tada; Hideki Asai; Naoki Maegawa; Yasuyuki Urisono; Keigo Saeki; Hidetada Fukushima
Journal:  Resusc Plus       Date:  2022-07-01

3.  Bacteriology of aspiration pneumonia in patients with acute coma.

Authors:  Enise Lauterbach; Frederik Voss; Roland Gerigk; Michael Lauterbach
Journal:  Intern Emerg Med       Date:  2014-08-28       Impact factor: 3.397

4.  Therapeutic hypothermia versus normothermia in adult patients with traumatic brain injury: a meta-analysis.

Authors:  Youfeng Zhu; Haiyan Yin; Rui Zhang; Xiaoling Ye; Jianrui Wei
Journal:  Springerplus       Date:  2016-06-21

5.  Early antibiotics administration during targeted temperature management after out-of-hospital cardiac arrest: a nationwide database study.

Authors:  Takashi Tagami; Hiroki Matsui; Masamune Kuno; Yuuta Moroe; Junya Kaneko; Kyoko Unemoto; Kiyohide Fushimi; Hideo Yasunaga
Journal:  BMC Anesthesiol       Date:  2016-10-07       Impact factor: 2.217

6.  Early-Onset Pneumonia in Non-Traumatic Out-of-Hospital Cardiac Arrest Patients with Special Focus on Prehospital Airway Management.

Authors:  Martin Christ; Katharina Isabel von Auenmueller; Scharbanu Amirie; Benjamin Michel Sasko; Michael Brand; Hans-Joachim Trappe
Journal:  Med Sci Monit       Date:  2016-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.